These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

473 related articles for article (PubMed ID: 23415889)

  • 1. Excess breast cancer risk in first degree relatives of CHEK2∗1100delC positive familial breast cancer cases.
    Adank MA; Verhoef S; Oldenburg RA; Schmidt MK; Hooning MJ; Martens JW; Broeks A; Rookus M; Waisfisz Q; Witte BI; Jonker MA; Meijers-Heijboer H
    Eur J Cancer; 2013 May; 49(8):1993-9. PubMed ID: 23415889
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26,000 patient cases and 27,000 controls.
    Weischer M; Bojesen SE; Ellervik C; Tybjaerg-Hansen A; Nordestgaard BG
    J Clin Oncol; 2008 Feb; 26(4):542-8. PubMed ID: 18172190
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CHEK2*1100delC homozygosity is associated with a high breast cancer risk in women.
    Adank MA; Jonker MA; Kluijt I; van Mil SE; Oldenburg RA; Mooi WJ; Hogervorst FB; van den Ouweland AM; Gille JJ; Schmidt MK; van der Vaart AW; Meijers-Heijboer H; Waisfisz Q
    J Med Genet; 2011 Dec; 48(12):860-3. PubMed ID: 22058428
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The CHEK2*1100delC variant acts as a breast cancer risk modifier in non-BRCA1/BRCA2 multiple-case families.
    Oldenburg RA; Kroeze-Jansema K; Kraan J; Morreau H; Klijn JG; Hoogerbrugge N; Ligtenberg MJ; van Asperen CJ; Vasen HF; Meijers C; Meijers-Heijboer H; de Bock TH; Cornelisse CJ; Devilee P
    Cancer Res; 2003 Dec; 63(23):8153-7. PubMed ID: 14678969
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Absence of CHEK2*1100delC mutation in families with hereditary breast cancer in North America.
    Iniesta MD; Gorin MA; Chien LC; Thomas SM; Milliron KJ; Douglas JA; Merajver SD
    Cancer Genet Cytogenet; 2010 Oct; 202(2):136-40. PubMed ID: 20875877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. German populations with infrequent CHEK2*1100delC and minor associations with early-onset and familial breast cancer.
    Rashid MU; Jakubowska A; Justenhoven C; Harth V; Pesch B; Baisch C; Pierl CB; Brüning T; Ko Y; Benner A; Wichmann HE; Brauch H; Hamann U;
    Eur J Cancer; 2005 Dec; 41(18):2896-903. PubMed ID: 16239104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CHEK2 1100delC and male breast cancer in the Netherlands.
    Wasielewski M; den Bakker MA; van den Ouweland A; Meijer-van Gelder ME; Portengen H; Klijn JG; Meijers-Heijboer H; Foekens JA; Schutte M
    Breast Cancer Res Treat; 2009 Jul; 116(2):397-400. PubMed ID: 18759107
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of breast cancer in women with a CHEK2 mutation with and without a family history of breast cancer.
    Cybulski C; Wokołorczyk D; Jakubowska A; Huzarski T; Byrski T; Gronwald J; Masojć B; Deebniak T; Górski B; Blecharz P; Narod SA; Lubiński J
    J Clin Oncol; 2011 Oct; 29(28):3747-52. PubMed ID: 21876083
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Breast cancer survival and tumor characteristics in premenopausal women carrying the CHEK2*1100delC germline mutation.
    Schmidt MK; Tollenaar RA; de Kemp SR; Broeks A; Cornelisse CJ; Smit VT; Peterse JL; van Leeuwen FE; Van't Veer LJ
    J Clin Oncol; 2007 Jan; 25(1):64-9. PubMed ID: 17132695
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CHEK2 1100delC is a susceptibility allele for HNPCC-related colorectal cancer.
    Wasielewski M; Vasen H; Wijnen J; Hooning M; Dooijes D; Tops C; Klijn JG; Meijers-Heijboer H; Schutte M
    Clin Cancer Res; 2008 Aug; 14(15):4989-94. PubMed ID: 18676774
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumour characteristics and prognosis of breast cancer patients carrying the germline CHEK2*1100delC variant.
    de Bock GH; Schutte M; Krol-Warmerdam EM; Seynaeve C; Blom J; Brekelmans CT; Meijers-Heijboer H; van Asperen CJ; Cornelisse CJ; Devilee P; Tollenaar RA; Klijn JG
    J Med Genet; 2004 Oct; 41(10):731-5. PubMed ID: 15466005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased risk of breast cancer associated with CHEK2*1100delC.
    Weischer M; Bojesen SE; Tybjaerg-Hansen A; Axelsson CK; Nordestgaard BG
    J Clin Oncol; 2007 Jan; 25(1):57-63. PubMed ID: 16880452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
    Piver MS
    Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CHEK2 1100delC is prevalent in Swedish early onset familial breast cancer.
    Margolin S; Eiberg H; Lindblom A; Bisgaard ML
    BMC Cancer; 2007 Aug; 7():163. PubMed ID: 17705858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene expression profiling assigns CHEK2 1100delC breast cancers to the luminal intrinsic subtypes.
    Nagel JH; Peeters JK; Smid M; Sieuwerts AM; Wasielewski M; de Weerd V; Trapman-Jansen AM; van den Ouweland A; Brüggenwirth H; van I Jcken WF; Klijn JG; van der Spek PJ; Foekens JA; Martens JW; Schutte M; Meijers-Heijboer H
    Breast Cancer Res Treat; 2012 Apr; 132(2):439-48. PubMed ID: 21614566
    [TBL] [Abstract][Full Text] [Related]  

  • 16. No increased susceptibility to breast cancer from combined CHEK2 1100delC genotype and the HLA class III region risk factors.
    de Jong MM; Nolte IM; Te Meerman GJ; van der Graaf WT; Oosterom E; Bruinenberg M; Steege Gv; Oosterwijk JC; van der Hout AH; Boezen HM; Schaapveld M; Kleibeuker JH; de Vries EG
    Eur J Cancer; 2005 Aug; 41(12):1819-23. PubMed ID: 16043347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased Risk for Other Cancers in Addition to Breast Cancer for CHEK2*1100delC Heterozygotes Estimated From the Copenhagen General Population Study.
    Näslund-Koch C; Nordestgaard BG; Bojesen SE
    J Clin Oncol; 2016 Apr; 34(11):1208-16. PubMed ID: 26884562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Homozygosity for a CHEK2*1100delC mutation identified in familial colorectal cancer does not lead to a severe clinical phenotype.
    van Puijenbroek M; van Asperen CJ; van Mil A; Devilee P; van Wezel T; Morreau H
    J Pathol; 2005 Jun; 206(2):198-204. PubMed ID: 15818573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estrogen receptor status in CHEK2-positive breast cancers: implications for chemoprevention.
    Cybulski C; Huzarski T; Byrski T; Gronwald J; Debniak T; Jakubowska A; Górski B; Wokołorczyk D; Masojć B; Narod SA; Lubiński J
    Clin Genet; 2009 Jan; 75(1):72-8. PubMed ID: 19021634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of CHEK2 missense variant I157T on the risk of breast cancer in carriers of other CHEK2 or BRCA1 mutations.
    Cybulski C; Górski B; Huzarski T; Byrski T; Gronwald J; Debniak T; Wokolorczyk D; Jakubowska A; Serrano-Fernández P; Dork T; Narod SA; Lubinski J
    J Med Genet; 2009 Feb; 46(2):132-5. PubMed ID: 18930998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.